GALE - Galena Biopharma, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Galena Biopharma, Inc.

2000 Crow Canyon Place
Suite 380
San Ramon, CA 94583
United States
855-855-4253
http://www.galenabiopharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees14

Key Executives

NameTitlePayExercisedAge
Mr. Stephen F. GhiglieriInterim Chief Exec. Officer, Chief Financial Officer and Principal Accounting Officer188.32kN/A55
Mr. Thomas J. Knapp J.D.Interim Gen. Counsel and Corp. Sec.427.69kN/A64
Dr. Bijan Nejadnik M.D.Chief Medical Officer and Exec. VP542.56kN/A55
Mr. John Thomas Burns CPAVP of Fin. and Corp. Controller235.6kN/A32
Ms. Remy Bernarda MBA, IRCSr. VP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Galena Biopharma, Inc., a biopharmaceutical company, develops hematology and oncology therapeutics that address unmet medical needs. The company develops GALE-401 (anagrelide controlled release), which completed Phase II clinical trial for the treatment of patients with myeloproliferative neoplasms to lower elevated platelet levels. It also develops NeuVax (nelipepimut-S), which is in Phase IIb clinical trial in combination with trastuzumab for HER2 1+ and 2+ node positive and high-risk node negative breast cancer patients; Phase II clinical trial in combination with trastuzumab for HER2 3+ breast cancer patients; Phase II clinical trial for women with ductal carcinoma in situ of the breast; and Phase II clinical trial for patients with gastric cancer. In addition, the company develops GALE-301 and GALE-302 for ovarian, endometrial, and breast cancers. It has strategic development and commercialization partnership with Dr. Reddy’s Laboratories Ltd. for NeuVax in breast and gastric cancers. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in San Ramon, California.

Corporate Governance

Galena Biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.